Long-term use of denosumab and its association with skeletal-related events and osteonecrosis of the jaw

Denosumab, an inhibitor of receptor activator of nuclear factor kappa-B ligand, reduces skeletal-related events (SREs) and is approved for solid tumors with bone metastases. We studied long-term denosumab efficacy and safety because real-world data is scarce. This single-arm, single-center retrospec...

Descripción completa

Detalles Bibliográficos
Autores principales: Fu, Pei-An, Shen, Chin-Yao, Yang, Shuen‑Ru, Lee, Chun-Hui, Chen, Hui-Wen, Lai, Edward Chia-Cheng, Chung, Wei-Pang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10209178/
https://www.ncbi.nlm.nih.gov/pubmed/37225727
http://dx.doi.org/10.1038/s41598-023-35308-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10209178/
https://www.ncbi.nlm.nih.gov/pubmed/37225727
http://dx.doi.org/10.1038/s41598-023-35308-z

Ejemplares similares